Search Results

Displaying Results 1-25 of 1257 "'MED'"

Jun 15, 2026, 10:25 ET 2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant

device was implanted for the first time into a deaf patient in Vienna. The Hochmairs went on to found the company MED-EL, which has continued to advance cochlear implant technology. MED-EL is now one of the world's largest manufacturers of hearing implants.In Australia, Graeme Clark, an ear, nose,

More news about: Broad Institute


Jun 15, 2026, 09:49 ET Top 5 Beverly Hills MD Plump + Firm Advanced Collagen Booster Reviews

Mexico to hold a Regenerative Medicine License. Continuing their commitment to innovation and beauty, Dr. Layke and Dr. Danielpour debuted their first med spa,

More news about: Beverly Hills MD


Jun 15, 2026, 08:47 ET Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

doi:10.1016/j.vetimm.2004.12.003iv Sykes JE, Francey T, Schuller S, Stoddard RA, Cowgill LD, Moore GE. Updated ACVIM consensus statement on leptospirosis in dogs. J Vet Intern Med. 2023 Nov-Dec;37(6):1966-1982. doi: 10.1111/jvim.16903v AAHA Guidelines vi Malter KB, et al. Vaccine 2022vii Levy

More news about: Elanco Animal Health


Jun 15, 2026, 08:15 ET CLUB MED ADVANCES STRATEGIC NORTH AMERICAN EXPANSION WITH THE REDEVELOPMENT OF CARAMBOLA BEACH RESORT IN ST. CROIX IN PARTNERSHIP WITH VICI PROPERTIES

partnership between Club Med and VICI. Following VICI's acquisition of the Carambola Beach Resort, VICI has entered into a long-term triple-net lease with Club Med, and will fund the resort's redevelopment, elevating the property to Club Med's Exclusive Collection standards. Club Med will run the future operations

More news about: Club Med


Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson; he has not been paid for any media work1 Mina R, et al. Talquetamab–daratumumab in relapsed or refractory myeloma. N Engl J Med. 13 June 2026.2 TALVEY. How TALVEY works. Accessed June 2026.

More news about: Johnson & Johnson


Jun 12, 2026, 12:06 ET Dr. Jacqueline Youtsos Scholarship Opens 2027 Applications for Pre-Medical and Medical Students

requirements:Currently enrolled as an undergraduate student at an accredited U.S. college or university, actively pursuing a medical career (pre-med, biology, health sciences, or related fields), ORCurrently enrolled as a medical student at an accredited U.S. M.D. or D.O.

More news about: Dr. Jacqueline Youtsos Scholarship


Jun 12, 2026, 08:59 ET From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch

across energy sectors — onto its board to lead the effort. The company simultaneously said it would seek a buyer for its clinical-stage oncology and med-tech operations.That diagnosis is backed by sobering data. The North American Electric Reliability Corporation projected in early 2026 that summer

More news about: USA News Group


Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.3

More news about: AbbVie


Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.3

More news about: AbbVie


Jun 11, 2026, 08:00 ET Consumer Edge Launches Taurus, Expanding Healthcare Intelligence Coverage with Hospital Purchase Data

of the med-tech space – from device purchasing to procedure utilization – and how that activity ultimately shows up in manufacturer revenue.Key capabilities of Taurus include:Manufacturer- and brand-level share analysis: Track competitive movement within med-tech categories

More news about: Consumer Edge


Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

2026.5 Tranekær S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. J Clin Med. 2021 Mar 17;10(6):1244. doi: 10.3390/jcm10061244. PMID: 33802848; PMCID: PMC8002719.6 Cherif, H, Cai, Q, Crivera, C, Leon, A, Rahman,

More news about: Johnson & Johnson


Jun 10, 2026, 15:51 ET 18 Ohio students advance to national finals of the Mott Million Dollar Challenge in Flint, Michigan

string musicians designed to be more durable and reliable than traditional rosin.Help Me — Molly Russell (6th Grade, Bio-Med Science Academy), social pitch: An app that helps students experiencing bullying connect with trusted adults, support resources and peer mentors.

More news about: Charles Stewart Mott Foundation


Jun 10, 2026, 11:01 ET Med-Metrix Enters Into Definitive Agreement to Acquire CanAide to Enhance Patient Access and Revenue Cycle Performance

the revenue cycle. Integrated into Med-Metrix's operator-led model and existing automations suite, these capabilities are expected to meaningfully improve operational and financial performance for Med-Metrix's clients."We are excited to welcome CanAide to Med-Metrix as we continue to expand the

More news about: Med-Metrix, LLC


Jun 10, 2026, 11:00 ET M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports

AirStrip Technologies, BL Healthcare, IBM, PharmaSecure, Microsoft, Apple, Ingenious Med, Cisco Networks, NeuroVigil, QxMD SoftwareGet Free Sample Report:

More news about: Valuates Reports


Jun 09, 2026, 09:31 ET Lung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer

1.Horn L, Mansfield AS, Szczęsna A, et al. N Engl J Med. 2018; 379(23): 2220-2229.↩2.

More news about: Lung Cancer Research Foundation


Jun 09, 2026, 08:01 ET Metabolic Supply Group (MSG) Launches MSG Trace™, the First Industry-Wide Transparency Platform for Compounded Medications

for compounded medications dispensed through participating pharmacy partners. Beginning July 1, 2026, MSG Trace will allow providers, clinics, med spas, and patients to verify the quality, potency, sterility, and sourcing information of all medications they receive through participating network

More news about: Metabolic Supply Group


Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study. Med Sci Monit. 2020;26:e927218. Published 2020 Nov 29. doi:10.12659/MSM.927218.7

More news about: RedHill Biopharma Ltd.


Jun 09, 2026, 06:43 ET Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation

the FSS Code, the 1994 and 2000 HSC Codes, and IMO MSC.1/Circ.1270, and is valid through 22 October 2030. An EC Type Examination Certificate (81823/A0 MED) was issued under the EU Marine Equipment Directive 2014/90/EU, supporting the wheelmark pathway for EU-flagged vessels and valid through 8 April 2031.

More news about: Fireaway


Jun 09, 2026, 02:00 ET VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway

J, Schoder V, Häuser W. Full-spectrum extract from Cannabis sativa DKJ127 for chronic back pain: a randomized, placebo-controlled phase 3 study. Nat Med (2025), published online on September 29, 2025, doi: 10.1038/s41591-025-03977-02 Meissner W, Argoff C, Sator S, Schoder V, Karst

More news about: Vertanical


Jun 09, 2026, 01:49 ET Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation

the FSS Code, the 1994 and 2000 HSC Codes, and IMO MSC.1/Circ.1270, and is valid through 22 October 2030. An EC Type Examination Certificate (81823/A0 MED) was issued under the EU Marine Equipment Directive 2014/90/EU, supporting the wheelmark pathway for EU-flagged vessels and valid through 8 April 2031.

More news about: Fireaway


Jun 09, 2026, 01:49 ET Fireaway erhält nach der Bewertung gemäß MSC.1/Circ.1270 die Typgenehmigung sowie die EU-/UK-Zertifizierung für Schiffsausrüstung für seine Stat-X®-Aerosol-Feuerlöschsysteme

der HSC-Codes von 1994 und 2000 sowie der IMO MSC.1/Circ.1270 erfüllen, und ist bis zum 22. Oktober 2030 gültig. Ein EG-Baumusterprüfzeugnis (81823/A0 MED) wurde gemäß der EU-Richtlinie 2014/90/EU über Schiffsausrüstung ausgestellt, das den „Wheelmark"-Weg für Schiffe unter EU-Flagge unterstützt und bis

More news about: Fireaway


Jun 09, 2026, 01:49 ET Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation

the FSS Code, the 1994 and 2000 HSC Codes, and IMO MSC.1/Circ.1270, and is valid through 22 October 2030. An EC Type Examination Certificate (81823/A0 MED) was issued under the EU Marine Equipment Directive 2014/90/EU, supporting the wheelmark pathway for EU-flagged vessels and valid through 8 April 2031.

More news about: Fireaway


Jun 09, 2026, 01:49 ET Fireaway obtient l'homologation de type et la certification européenne et britannique relative aux équipements marins pour les systèmes d'extinction d'incendie par aérosols condensés Stat-X® à l'issue de l'évaluation MSC.1/Circ.1270

HSC de 1994 et 2000 et de la circulaire MSC.1/Circ.1270 de l'OMI. Il est valable jusqu'au 22 octobre 2030. Un certificat d'examen CE de type (81823/A0 MED) a été délivré en vertu de la directive 2014/90/UE relative aux équipements marins, soutenant le marquage « barre à roue » pour les navires battant pavillon

More news about: Fireaway


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.